Paik PK - Search Results

1

Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.

Yang SR, Gedvilaite E, Ptashkin R, Chang J, Ziegler J, Mata DA, Villafania LB, Nafa K, Hechtman JF, Benayed R, Zehir A, Benhamida J, Arcila ME, Mandelker D, Rudin CM, Paik PK, Drilon A, Schoenfeld AJ, Ladanyi M. Yang SR, et al. Among authors: paik pk. J Thorac Oncol. 2024 Mar;19(3):409-424. doi: 10.1016/j.jtho.2023.10.004. Epub 2023 Oct 12. J Thorac Oncol. 2024. PMID: 37838086

2

Selective regulation of IL-10 signaling and function by zymosan.

Du Z, Kelly E, Mecklenbräuker I, Agle L, Herrero C, Paik P, Ivashkiv LB. Du Z, et al. J Immunol. 2006 Apr 15;176(8):4785-92. doi: 10.4049/jimmunol.176.8.4785. J Immunol. 2006. PMID: 16585572

3

IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins.

Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB. Hu X, et al. Among authors: paik pk. Immunity. 2006 May;24(5):563-74. doi: 10.1016/j.immuni.2006.02.014. Immunity. 2006. PMID: 16713974 Free article.

4

Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase association.

van Leeuwen JE, Paik PK, Samelson LE. van Leeuwen JE, et al. Among authors: paik pk. J Biol Chem. 1999 Feb 19;274(8):5153-62. doi: 10.1074/jbc.274.8.5153. J Biol Chem. 1999. PMID: 9988765 Free article.

5

Evaluating sleep in covert encephalopathy with wearable technology: results from the WATCHES study.

Buckholz A, Clarke L, Paik P, Jesudian A, Schwartz R, Krieger A, Rosenblatt R, Brown RS Jr. Buckholz A, et al. Hepatol Commun. 2023 Feb 1;7(2):e0002. doi: 10.1097/HC9.0000000000000028. eCollection 2023 Feb 1. Hepatol Commun. 2023. PMID: 36724117 Free PMC article.

6

The oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding domain-dependent negative regulation of ZAP-70 by c-Cbl in Jurkat T cells.

van Leeuwen JE, Paik PK, Samelson LE. van Leeuwen JE, et al. Among authors: paik pk. Mol Cell Biol. 1999 Oct;19(10):6652-64. doi: 10.1128/MCB.19.10.6652. Mol Cell Biol. 1999. PMID: 10490604 Free PMC article.

7

Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors.

Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, Lowell CA, Ivashkiv LB. Tassiulas I, et al. Nat Immunol. 2004 Nov;5(11):1181-9. doi: 10.1038/ni1126. Epub 2004 Oct 3. Nat Immunol. 2004. PMID: 15467722

8

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.

Paik PK, Krug LM. Paik PK, et al. J Thorac Oncol. 2010 Feb;5(2):275-9. doi: 10.1097/JTO.0b013e3181c5e366. J Thorac Oncol. 2010. PMID: 20035240 Free PMC article. Review.

9

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. Paik PK, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-85. doi: 10.1007/s00280-010-1265-5. Epub 2010 Feb 18. Cancer Chemother Pharmacol. 2010. PMID: 20165849 Free PMC article. Clinical Trial.

10

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Paik PK, et al. J Clin Oncol. 2011 May 20;29(15):2046-51. doi: 10.1200/JCO.2010.33.1280. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483012 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page